BioSpace News Archive

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced that that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update and participate in a panel at the 2020 BIO CEO & Investor Conference.

HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest independent health savings account (“HSA”) custodian, announced that it plans to release its fiscal year-end sales results following the close of regular stock market trading hours on Tuesday, February 18, 2020.

Encompass Health Corp., a national leader in integrated healthcare services, announced that it will host an investor day on March 4, 2020.

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the start of a pivotal study to determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent for methods of screening for anti-PVRIG antibodies that inhibit the binding of PVRIG with PVRL2

Bausch Health Companies Inc. announced that the Company will participate in three investor conferences.

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first patient was implanted in the Company’s U.S. human clinical study for its EVO ICL family of lenses.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study)

Syntrix Pharmaceuticals announces the discovery that desmetramadol is a G-protein biased opioid receptor agonist.

McKesson Corporation (NYSE:MCK) today reported results for the third quarter ended December 31, 2019.